Two biotechs this week topped the $100 million mark in their respective initial public offerings, both of which were able to offer more shares than planned. One, a company with nearly nine month’s-worth of revenue from a newly commercialized drug and the other, an early-clinical stage oncology drug developer, illustrate the range of biotech companies eliciting public investor interest this summer.

Inhibrx (NASDAQ: INBX), a biotech in La Jolla, CA, pulled in $119 million to advance its Phase 1 programs, which are evaluating single-domain antibodies the company has designed to treat cancer and rare diseases. The biotech offered 7 million… Read more »